In Vitro Cytotoxicity Effects of Encapsulated Disulfiram on Gemcitabine (dFdC) Acquired Resistant BT 549 Triple Negative Breast Cancer Cells

The prevalence of cancer is predicted to increase globally, making it one of the leading causes of mortality. The creation of novel and effective pharmacotherapeutics can increase cancer patients' chances of survival and lower their mortality rate. However, the significant cost and time involved in producing new anticancer medications make it difficult, and continuous use of these chemotherapeutic medications might lead to resistance. A practical alternative approach is drug repurposing, which involves using licensed medications with noteworthy pharmacokinetic and toxicological properties to treat different illnesses. It has been claimed that disulfiram (DS), a medication licensed to treat chronic alcoholism with few side effects, has anticancer action both in vitro and in vivo. However, DS's poor solubility in aqueous solutions and high instability in biological mediums limit its cytotoxic effect. The bioavailability of DS can be increased by using drug delivery vehicles. We created an encapsulated DS using polymeric micelles, and the results of our research revealed that the cytotoxic impact on the resistant cell line BT 549GEM100nM was drastically enhanced because the half-life of DS in the encapsulated micelles was significantly extended.